To slow down Alzheimer's relentless attack on the brain, scientists have developed a drug, which will be available in 5 years.
Tests have shown that solanezumab delays the pace of decline by more than a third in those with a mild form of the disease, the Daily Express reported.
Vitamin D Ineffective Against Cancer, Diabetes and Dementia
A new research has now cast doubt over the efficacy of vitamin D in providing protection against cancer, dementia and diabetes
Advertisement
Researchers also believe that the treatment could one day be used like statins, with a single jab given to patients before they start showing symptoms of the disease.
Dr Eric Karran, director of research at Alzheimer's UK, has said they were "full of hope" that the drug, which could help "unlock" the secrets of the disease, will be made available to people before the end of the decade.
![Why Promising Dementia Drugs Failed in Clinical Trials Explained]( "Why Promising Dementia Drugs Failed in Clinical Trials Explained")
The most common cause of dementia among older people, Alzheimer's disease, currently has no effective drugs to stop, slow or prevent disease progression.
He said in a conference that if solanezumab is shown to work in mild Alzheimer's disease then the pathway would be to take that earlier.
The drug works by targeting a toxic protein in the brain called beta amyloid, which can build up for a decade before any outward signs of dementia such as memory loss.
Karran said that if its combined with a battery of early detection tests involving scans and memory, treatments could one day lead to "biomarker" tests to accurately spot those at risk before the disease strikes.
People aged between the age of 55 to 90 are being recruited for a study in the US, to examine the drug's effects in people with mild Alzheimer's.
Source: ANI
Why Promising Dementia Drugs Failed in Clinical Trials Explained
The most common cause of dementia among older people, Alzheimer's disease, currently has no effective drugs to stop, slow or prevent disease progression.
Advertisement
He said in a conference that if solanezumab is shown to work in mild Alzheimer's disease then the pathway would be to take that earlier.
The drug works by targeting a toxic protein in the brain called beta amyloid, which can build up for a decade before any outward signs of dementia such as memory loss.
Karran said that if its combined with a battery of early detection tests involving scans and memory, treatments could one day lead to "biomarker" tests to accurately spot those at risk before the disease strikes.
People aged between the age of 55 to 90 are being recruited for a study in the US, to examine the drug's effects in people with mild Alzheimer's.
Source: ANI
Gentler Heart Surgery may Prevent Onset of Dementia
Previous research has indicated that aortic valve stenosis is the most frequent heart valve defect of older people in Europe.
Advertisement
 44 Million Now Suffer from Dementia Worldwide: ReportA new report finds the number of people suffering from dementia has risen 22 percent in the past three years, with 44 million people living with the disease worldwide. | Advertisement
|
Advertisement
Recommended Readings
Latest Research News
The AI method shows promise in identifying imaging biomarkers for diagnosing ADHD.
Diagnosed autistic individuals showed increased premature mortality in the UK, highlighting urgent needs to address associated inequalities.
Study reveals a correlation between hearing impairment and distinct brain region variances, contributing to dementia.
Financial impact of caring for individuals with neurodegenerative disorders reaches hundreds of billions annually in the United States.
Experts emphasize that addressing the skills gap demands immediate attention and innovative solutions, including education, re-training, and significant time investment.